CANTARGIA AB |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.727 SEK | +1.26% |
|
+5.68% | +27.45% |
Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.
Calendar
28/08/2024
- Q2 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.668
SEK
Average target price
12.67
SEK
Spread / Average Target
+171.35%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +27.45% | 81.15M | |
| +16.49% | 122B | |
| +21.73% | 115B | |
| +22.15% | 26.64B | |
| -21.81% | 19.91B | |
| -16.87% | 16.32B | |
| -18.81% | 15.49B | |
| -44.74% | 15.52B | |
| +62.72% | 14.83B | |
| +3.09% | 13.67B |
- Stock Market
- Equities
- CANTA Stock
- News Cantargia AB
- Cantargia Appoints New Chief Business Officer
